



## TOTECT<sup>®</sup> PRODUCT UPDATE

### *TopoTarget USA, Inc. Introduces Totect<sup>®</sup> Kit with New Price Option*

TopoTarget USA, Inc. is offering a new lower-priced option for a complete Totect<sup>®</sup> (dexrazoxane for injection) emergency kit for the treatment of anthracycline extravasation (AEV). The new Totect<sup>®</sup> kit will be priced at \$6,500 for the full three-day emergency treatment as of September 18, 2008.

The new pricing option will help increase access to Totect<sup>®</sup> for oncology practices, hospitals, infusion centers, and clinics. Small local and regional physician practices and hospitals treat the majority of AEVs in the U.S., so under the new price, these organizations should have greater ability to stock Totect<sup>®</sup>. TopoTarget is committed to helping make Totect<sup>®</sup> accessible and within arms reach to treat patients within six hours after an AEV. Clinical studies show that treatment of AEV with Totect<sup>®</sup> within this critical six-hour window significantly reduces the need for surgical debridement.

In addition to its commitment to providing greater access to Totect<sup>®</sup>, TopoTarget supports extravasation education and awareness programs with numerous professional organizations, including the Hematology/Oncology Pharmacists Association (HOPA), the American Society of Health System Pharmacists (ASHP), the Oncology the Nursing Society (ONS) and the American Society of Clinical Oncology (ASCO), among others. TopoTarget also provides education for patients and caregivers as well as dedicated telephone support for reimbursement.

Since the introduction of Totect<sup>®</sup> to the U.S. market in October 2007, our goal has been to make this treatment accessible and readily available to all cancer patients receiving chemotherapy with an anthracycline-containing regimen, says John L. Parsons, Jr., President, TopoTarget USA, Inc. and Chief Commercial Officer, TopoTarget A/S.

According to Jim Koeller, MS and Professor at the University of Texas at Austin and the Health Science Center in San Antonio, "This decision by TopoTarget is a move to ensure that all practices have available an evidence-based treatment for chemotherapy extravasation without the worry of significant negative financial consequence. Although rare, extravasation has the potential to cause great patient morbidity at costs that can be excessive."

### **About Totect<sup>®</sup> for Anthracycline Extravasations**

- Totect<sup>®</sup> is the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the treatment of AEVs .
- Extravasation of anthracyclines can cause severe tissue damage that, if untreated, may require surgical intervention, and can delay patients' chemotherapy regimens.
- Emergency administration of Totect<sup>®</sup> via intravenous infusion must take place immediately after, and no later than six hours after, the extravasation. The patient then receives treatment for two consecutive days following the initial emergency administration.
- The Totect<sup>®</sup> package contains a complete kit for the treatment of a single patient. Full prescribing information is available at [www.totect.com](http://www.totect.com).
- TopoTarget USA, Inc. is exploring the possibility of replacement Totect<sup>®</sup> vials to support the Totect<sup>®</sup> emergency treatment kit.

## **Ordering Totect®**

Totect® is available in the United States through ASD Healthcare and Oncology Supply (both AmerisourceBergen companies), and through Cardinal Specialty Distribution. To order Totect® please call ASD Healthcare at (800) 746-6273 or Cardinal Specialty Distribution at (866) 677-4844. When ordering, please indicate if you are interested in the new lower-priced Totect® option at \$6,500 or the extended 6-year replacement guarantee option.

For general information on Totect® please visit [www.totect.com](http://www.totect.com) or call (866) 914-2922.

**Contraindications:** None known **Warnings:** Pregnancy Category D **Precautions:** Totect® is a cytotoxic drug. When administered to patients receiving anthracycline containing cytotoxic therapy, additive cytotoxicity may occur. Treatment with Totect® is associated with leukopenia, neutropenia, and thrombocytopenia. Hematological monitoring should be performed. Reversible elevations of liver enzymes may occur with dexrazoxane. **Patients with Moderate or Severe Renal Insufficiency:** Greater exposure to dexrazoxane may in occur in patients with compromised renal function. The Totect® dose should be reduced by 50% in patients with creatinine clearance values <40mL/min. Dimethylsulfoxide (DMSO) should not be used in patients who are receiving dexrazoxane to treat anthracycline-induced extravasation. **Laboratory Tests:** Blood counts and liver enzymes should be monitored. **Adverse Reactions:** Dexrazoxane has been studied previously as a cytotoxic agent. Adverse reactions of nausea/vomiting, diarrhea, stomatitis, bone marrow suppression (neutropenia, thrombocytopenia), altered liver function (increased AST/ALT), and infusion site burning have been observed. These adverse reactions have been reversible.